Notice of Annual General Meeting in DiaGenic ASA
The board of directors of DiaGenic ASA (the “Company”) hereby convenes the annual general meeting for 2013.
Time: 23 May 2013 at 10:00 hours (CET)
Place: Grenseveien 92, Oslo, Norway
Agenda:
- Opening of the meeting by chairman of the board Henrik Lund, including registration of shareholders present
- Election of chairman of the meeting and a person to co-sign the minutes
- Approval of notice and agenda
- Approval of the annual accounts and the annual report for the financial year 2012
- The board of directors’ declaration on salary and other remuneration to the executive management
- Remuneration to the auditor
- Election of board members
- Remuneration to the board members
- Remuneration to the members of the nomination committee
- Election of members to the nomination committee
- Share capital reduction by reducing the par value
- Reverse share split
- Board authorisation for share capital increase
To item 4 on the agenda:
The annual financial statements, the Director's report and the auditor's statement are enclosed in the Annual Report which was sent to Oslo Stock Exchange in a notice of 22 March.
To item 7 and 8 on the agenda:
The Nomination Committee proposal will be available on the Company’s web page www.diagenic.com at the latest on the same date as the general meeting is held.
Shareholders who cannot participate at the general meeting in person may authorize the chairman of the board or another person to vote for their shares by using the attached proxy form. The chairman of the board will only accept proxies with instructions, so that it is stated how the proxy holder shall vote in each matter. The written proxy form, dated and signed, may be sent to DiaGenic ASA c/o DNB Bank ASA, Verdipapirservice, NO-0021 Oslo, Norway, or per fax +47 22 48 11 71 or presented at the latest at the general meeting. Web-based registration of the proxy is also available, through “Investortjenester”, a service provided to the individual investor by most Norwegian registrars. The reference number is required for registration. Online registration is not available for registration of voting instructions. The proxy form (scanned) may also be sent by email to genf@dnb.no. If the shareholder is a company, please attach the shareholder’s certificate of registration to the proxy. Proxy forms which are sent to DNB Bank Verdipapirservice must be received no later than 21 May 2013.
Pursuant to the Company’s articles of association section 10, it is decided that shareholders and proxy holders who wish to participate at the general meeting, must notify the Company of his/her presence by use of the attached attendance form. The attendance form may be sent to DiaGenic ASA c/o DNB Bank ASA, Verdipapirservice, NO-0021 Oslo, Norway, or fax to +47 22 48 11 71. Attendance may also be registered on the Company’s website www.diagenic.com or through “Investortjenester”. The reference number is required for registration through “Investortjenester” and in addition the pin code through the Company’s website. Alternatively, the attendance form (scanned) may be sent per email to genf@dnb.no. The attendance form must be received by DNB Bank Verdipapirservice no later than 21 May 2013.
Information regarding the ordinary general meeting, including this notice with attachments is available at the Company's website www.diagenic.com
Oslo, 30 April 2013
On behalf of the Board of directors of DiaGenic ASA
Henrik Lund
Chairman of the Board
Telephone: +47 909 71 219
E-mail: henrik.lund@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com